key: cord-0733958-k5kbrp05 authors: Romanelli, Antonio; Mascolo, Silvia title: Immunosuppression drugā€related and clinical manifestation of Coronavirus disease 2019: A therapeutical hypothesis date: 2020-04-15 journal: Am J Transplant DOI: 10.1111/ajt.15905 sha: 2b463a32a405e22bfc52ba3f4f291809f9207c77 doc_id: 733958 cord_uid: k5kbrp05 We read with interest the article of Guillen et al. 1 . Here, the authors described the management of a kidney transplanted patient infected by SARS-CoV-2 that causes novel Coronavirus disease 2019 (COVID-19). The authors stated that immunosuppressed patients might present with atypical clinical manifestation (fever, diarrhea, fatigue) without respiratory symptoms. Also Li and colleagues 2 reported SARS-CoV-2 infection in two solid organ transplanted patients. The two heart transplanted patients presented with variable severity of COVID-19 (one mild and another with more severe manifestations requiring a prolonged hospitalization), however, both survived the event. To the Editor: We read with interest the article of Guillen et al. 1 Here, the authors described the management of a kidney transplanted patient in- Actually, except for the case reports mentioned above, we found no data about the incidence and outcome of COVID-19 in this cluster of patients. Furthermore, immunosuppressive drugs could be a valid "therapeutic" choice, reducing the activity of the T cell immune system and preventing organ injury. Case report of COVID-19 in a kidney transplant recipient: does immunosuppression alter the clinical presentation? First cases of COVID-19 in heart transplantation from China Pathological findings of COVID-19 associated with acute respiratory distress syndrome COVID-19: yet another coronavirus challenge Impact of mycophenolic acid and tacrolimus on Th17-related immune response